ABCA1 and kidney disorder: The above studies suggest that targeting cholesterol efflux represents a new promising therapeutic strategy to ameliorate lipotoxicity-mediated renal injury in renal diseases of metabolic and non-metabolic origin, and that the beneficial effect can be achieved in an ABCA1-dependent or independent manner.